Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
WHITELEY v. ZYNERBA PHARMACEUTICALS, INC. et al
Case Number:
2:19-cv-04959
Court:
Nature of Suit:
Other Statutes: Securities/Commodities
Multi Party Litigation:
Class Action
Judge:
Firms
-
September 17, 2021
3 Firms Win $1.3M In Fees From Zynerba CBD Gel Settlement
A Pennsylvania federal judge has granted final approval for an award of $1.3 million in fees to attorneys from Pomerantz LLP, the Rosen Law Firm and Bronstein Gewirtz & Grossman LLC for securing a $4 million settlement on behalf of investors in CBD drugmaker Zynerba Pharmaceuticals Inc.
-
July 28, 2021
3 Firms Seek $1.3M In Fees From Zynerba CBD Gel Settlement
Pomerantz LLP, the Rosen Law Firm and Bronstein Gewirtz & Grossman LLC want more than $1.3 million for securing a $4 million settlement on behalf of investors claiming that CBD drugmaker Zynerba Pharmaceuticals Inc. failed to disclose unfavorable results from a clinical trial.
-
May 14, 2021
Philly Judge OKs Investors' $4M CBD Study Settlement Deal
A federal judge in Philadelphia has given an initial nod to a $4 million settlement agreement that would end investor claims that the CBD drugmaker Zynerba Pharmaceuticals Inc. withheld adverse details about a clinical trial.
-
May 03, 2021
CBD Co. Zynerba, Investors Seek OK For $4M Settlement Deal
Investors in CBD drugmaker Zynerba Pharmaceuticals have asked a federal judge in Pennsylvania to approve a $4 million settlement deal that would end claims that the company withheld unfavorable information about a clinical trial for a drug candidate.
-
March 09, 2021
CBD Co. Zynerba, Investors Aim To Settle Drug Trial Claims
CBD drugmaker Zynerba Pharmaceuticals and a proposed class of shareholders told a federal judge in Philadelphia that they expect to soon finalize details of a settlement that, if approved, will end claims that the company withheld adverse clinical trial results.
-
June 25, 2020
Investors Fight CBD Co.'s Bid To Ax Suit Over Clinical Trial
Investors accusing CBD drugmaker Zynerba Pharmaceuticals of withholding worrisome clinical trial results from the public have told a Pennsylvania federal court that the company can't beat their proposed class action by relying on its own self-serving interpretations of the data.